인간 마이크로바이옴 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Human Microbiome Market

The future of the global human microbiome market looks promising with opportunities in the therapeutic and diagnostic markets. The global human microbiome market is expected to reach an estimated $4.1 billion by 2035 with a CAGR of 14.7% from 2026 to 2035. The major drivers for this market are the rising adoption of precision nutrition approaches, the growing use for personalized medicine and therapies, and the increasing clinical trials in microbiome therapeutics.

• Lucintel forecasts that, within the product category, probiotic is expected to witness the highest growth over the forecast period due to the increasing consumer preference for preventive health solutions.
• Within the application category, therapeutic is expected to witness higher growth due to the growing research on microbiome-based disease treatments.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding healthcare investments and rising awareness levels.

Emerging Trends in Human Microbiome Market

The human microbiome market is experiencing rapid growth driven by advances in biotechnology, increasing awareness of microbiome health, and a surge in research and development activities. As scientific understanding deepens, new products and therapies are emerging, transforming healthcare approaches. This market is also influenced by technological innovations, personalized medicine trends, and a rising demand for microbiome-based diagnostics and therapeutics. These developments are not only expanding market size but also reshaping how health conditions are diagnosed and treated. The following key trends highlight the major shifts currently shaping the human microbiome market and its future trajectory.

• Growing Investment in Microbiome Research: Increased funding from both public and private sectors is accelerating discoveries in microbiome science. This investment supports large-scale studies, development of new diagnostic tools, and innovative therapies. As research uncovers more about microbiome functions, the market benefits from a broader pipeline of products, attracting biotech firms and pharmaceutical companies. This trend enhances the credibility and scientific foundation of microbiome-based solutions, leading to more targeted and effective health interventions, ultimately expanding market opportunities and fostering innovation.
• Advances in Personalized Microbiome Therapies: Personalized medicine is increasingly integrated into microbiome-based treatments. By analyzing individual microbiome profiles, companies develop tailored probiotics, prebiotics, and microbiome modulators. This customization improves treatment efficacy and reduces adverse effects, appealing to consumers seeking personalized health solutions. The trend drives the market toward precision therapies, encouraging the development of diagnostic tools and bespoke formulations. As a result, personalized microbiome therapies are becoming a significant segment, transforming traditional one-size-fits-all approaches into more effective, individualized healthcare options.
• Expansion of Microbiome Diagnostics and Testing: The demand for microbiome testing kits and diagnostic services is rising sharply. These tests help identify microbiome imbalances linked to various health conditions, enabling early diagnosis and targeted treatment plans. Companies are developing non-invasive, rapid testing methods, making microbiome analysis more accessible to consumers and clinicians. This trend enhances disease management, supports preventive healthcare, and fuels market growth. As microbiome diagnostics become more sophisticated and affordable, they are poised to become standard components of routine health assessments, broadening the scope of microbiome applications in clinical practice.
• Integration of Microbiome Data with Digital Health Technologies: The convergence of microbiome research with digital health platforms, including AI and machine learning, is revolutionizing data analysis and interpretation. These technologies enable large-scale data integration, pattern recognition, and predictive modeling, leading to more accurate diagnostics and personalized treatment strategies. Digital tools facilitate remote monitoring and real-time health management, making microbiome-based solutions more user-friendly and scalable. This integration accelerates innovation, enhances patient engagement, and opens new avenues for market expansion, positioning microbiome data as a cornerstone of future healthcare ecosystems.
• Rising Consumer Awareness and Market Adoption: Increasing public awareness about the importance of microbiome health is driving consumer demand for probiotic foods, supplements, and wellness products. Educational campaigns and scientific publications are demystifying microbiome benefits, encouraging proactive health management. This trend boosts retail sales and supports the development of new consumer-oriented products. As awareness grows, healthcare providers are more likely to recommend microbiome-based interventions, further integrating these solutions into mainstream healthcare. The shift toward preventive and holistic health approaches is expanding the market beyond clinical settings into everyday wellness, fostering sustained growth and innovation.

These trends are collectively reshaping the human microbiome market by fostering innovation, enhancing personalized healthcare, expanding diagnostic capabilities, integrating digital technologies, and increasing consumer engagement. This evolution is positioning the market for substantial growth and a pivotal role in future healthcare paradigms.

Recent Developments in the Human Microbiome Market

The human microbiome market is experiencing rapid growth driven by advances in biotechnology, increasing awareness of microbiome health, and expanding applications in medicine and wellness. Innovations in sequencing technologies and personalized treatments are fueling new opportunities. As research uncovers the microbiome's role in various diseases, the market is poised for significant expansion. This evolving landscape offers promising prospects for healthcare providers, biotech firms, and consumers seeking targeted therapies and health optimization solutions.

• Growing Demand for Personalized Medicine: The increasing understanding of individual microbiomes is enabling tailored treatments, improving efficacy, and reducing side effects. This personalization is attracting investments and fostering innovation in diagnostics and therapeutics, which enhances patient outcomes and opens new revenue streams for biotech companies.
• Advances in Sequencing Technologies: Cutting-edge sequencing methods have reduced costs and increased accuracy, allowing for comprehensive microbiome analysis. These technological improvements facilitate large-scale studies, accelerate discovery of microbiome-based therapies, and expand market access across healthcare and research sectors.
• Rising Prevalence of Chronic Diseases: The surge in conditions like obesity, diabetes, and inflammatory diseases highlights the microbiome's role in health. This trend drives demand for microbiome-targeted interventions, fostering market growth as companies develop probiotics, prebiotics, and microbiome-modulating drugs to address unmet medical needs.
• Increasing Investment and Collaborations: Public and private sector funding, along with strategic partnerships, are accelerating research and product development. These collaborations enhance innovation, streamline regulatory pathways, and expand market reach, ultimately boosting the commercialization of microbiome-based solutions.
• Expansion Into Wellness and Consumer Markets: The adoption of microbiome testing kits and probiotic products in the wellness industry is growing rapidly. This diversification into consumer health markets broadens revenue streams, increases awareness, and promotes preventive health strategies, contributing to overall market expansion.

The human microbiome market is witnessing transformative developments that are expanding its scope and applications. These opportunities are driving innovation, improving healthcare outcomes, and attracting significant investments. As a result, the market is poised for sustained growth, offering benefits across medical, research, and consumer sectors, ultimately shaping the future of personalized health and wellness solutions.

Strategic Growth Opportunities in the Human Microbiome Market

The human microbiome market is experiencing rapid growth driven by advances in research, personalized medicine, and increasing awareness of microbiome health benefits. Innovations in sequencing technologies and a focus on microbiome-based therapeutics are expanding applications across healthcare, wellness, and diagnostics. As scientific understanding deepens, opportunities for targeted interventions and preventive healthcare are emerging, creating a dynamic landscape for industry players to capitalize on. This evolving market promises significant contributions to disease management, health optimization, and personalized treatment strategies.

• Expansion of Microbiome-Based Therapeutics for Gastrointestinal and Autoimmune Diseases: Developing targeted probiotic, prebiotic, and microbiome transplant therapies offers promising solutions for chronic conditions, improving patient outcomes and reducing healthcare costs. Advances in understanding microbiome-disease links enable precision medicine approaches, fostering new drug development pipelines. This growth opportunity involves integrating microbiome modulation into standard care, expanding clinical trials, and gaining regulatory approvals to meet rising demand for innovative treatments.
• Increasing Adoption of Microbiome Diagnostics for Personalized Health Assessment: Microbiome testing enables detailed analysis of individual microbial compositions, facilitating personalized health insights and early disease detection. The rise of at-home testing kits and clinical diagnostics enhances preventive care and tailored treatment plans. This opportunity is driven by technological advancements in sequencing and bioinformatics, making microbiome profiling more accessible, accurate, and cost-effective, thereby transforming traditional diagnostic paradigms.
• Growing Interest in Microbiome Research for Mental Health and Neurodegenerative Disorders: Emerging evidence links microbiome health to mental well-being and neurological conditions, opening avenues for novel interventions. Research into gut-brain axis mechanisms supports development of microbiome-targeted therapies for depression, anxiety, and neurodegenerative diseases. This expanding field attracts investment, fostering innovation in psychobiotics and microbiome modulation strategies to improve mental health outcomes.
• Rising Demand for Microbiome-Based Products in The Wellness and Beauty Sectors: The consumer shift towards holistic health and natural products fuels growth in microbiome skincare, supplements, and functional foods. Brands leverage microbiome science to promote gut health and skin vitality, appealing to health-conscious consumers. This market expansion involves product innovation, marketing strategies emphasizing scientific backing, and regulatory navigation to meet consumer expectations and capitalize on wellness trends.
• Increasing Integration of Microbiome Insights Into Personalized Medicine and Healthcare Strategies: Incorporating microbiome data into clinical decision-making enhances treatment efficacy and disease prevention. Personalized microbiome profiles inform tailored interventions, from diet plans to medication choices, optimizing health outcomes. This opportunity is supported by advancements in data analytics, AI, and collaborative research, enabling healthcare providers to adopt microbiome-informed approaches and revolutionize patient care.

The overall growth opportunities in the human microbiome market are poised to significantly influence healthcare, diagnostics, and consumer wellness sectors. By harnessing scientific innovations and expanding applications, industry stakeholders can drive personalized, preventive, and effective health solutions. These opportunities will likely accelerate market expansion, foster new product development, and improve patient outcomes, establishing the human microbiome as a cornerstone of future healthcare paradigms.

Human Microbiome Market Drivers and Challenges

The human microbiome market is influenced by a complex interplay of technological advancements, economic factors, and regulatory frameworks. Innovations in sequencing technologies and microbiome research have expanded understanding and capabilities, driving market growth. Economic factors such as increasing healthcare expenditure and rising prevalence of microbiome-related diseases further propel demand. Regulatory policies and approvals shape product development and commercialization, impacting market dynamics. However, challenges like scientific uncertainties, regulatory hurdles, and ethical concerns pose significant barriers. Understanding these drivers and challenges is essential for stakeholders to navigate the evolving landscape and capitalize on emerging opportunities within the human microbiome market.

The factors responsible for driving the human microbiome market include:

• Technological Innovations: The rapid development of next-generation sequencing (NGS) and bioinformatics tools has revolutionized microbiome research. These technologies enable detailed analysis of microbial communities, facilitating the discovery of novel therapeutic targets and diagnostics. As sequencing becomes faster and more affordable, research institutions and companies can accelerate product development, leading to increased market activity. Additionally, advancements in personalized medicine and microbiome-based therapies are opening new avenues for treatment, further fueling market growth. The integration of artificial intelligence and machine learning enhances data analysis, making microbiome insights more actionable and expanding commercial applications.
• Rising Prevalence of Microbiome-Related Diseases: Increasing incidences of conditions such as inflammatory bowel disease, obesity, diabetes, and autoimmune disorders are driving demand for microbiome-based diagnostics and therapeutics. As awareness grows about the microbiome's role in health and disease, patients and healthcare providers are seeking targeted interventions. This trend is supported by epidemiological data indicating a global rise in these conditions, especially in developed countries. Consequently, pharmaceutical and biotech companies are investing heavily in microbiome research to develop innovative products, which significantly boosts market growth and diversification.
• Growing Investment and Funding: The human microbiome market benefits from substantial investments from venture capitalists, government agencies, and private organizations. Funding supports research initiatives, clinical trials, and product commercialization efforts. Increased financial backing accelerates innovation, reduces time-to-market, and enhances competitive positioning. Governments are also establishing regulatory pathways and grants to promote microbiome research, creating a conducive environment for market expansion. This influx of capital encourages startups and established players to develop novel microbiome-based solutions, fostering a dynamic and competitive landscape that propels market growth.
• Increasing Adoption of Microbiome-Based Therapies: The shift towards personalized and precision medicine is driving the adoption of microbiome-based therapies. These therapies, including probiotics, prebiotics, and fecal microbiota transplants, are gaining acceptance among clinicians for their potential to treat complex diseases. Growing clinical evidence and positive patient outcomes are further encouraging healthcare providers to incorporate microbiome interventions into treatment regimens. Additionally, the development of regulatory approvals and guidelines enhances confidence in these therapies, leading to broader adoption across hospitals, clinics, and wellness centers, thereby expanding the market.
• Expansion of Microbiome Research and Collaborations: Collaborative efforts between academia, biotech firms, and pharmaceutical companies are expanding the scope of microbiome research. These partnerships facilitate knowledge sharing, resource pooling, and accelerated innovation. Large-scale projects and consortia are mapping microbial diversity and functions, providing valuable insights for product development. Such collaborations also help in standardizing methodologies and establishing regulatory standards, which are crucial for commercialization. The expanding research landscape attracts more stakeholders and investment, creating a robust ecosystem that sustains long-term market growth.

The challenges in the human microbiome market are:

• Scientific Uncertainties and Variability: Despite significant progress, microbiome research faces challenges related to scientific uncertainties and variability in results. Microbial communities are highly complex and individualized, making it difficult to establish universal biomarkers or therapeutic targets. Variability in sample collection, analysis methods, and data interpretation can lead to inconsistent findings, hindering regulatory approval and clinical adoption. This scientific ambiguity creates hesitation among investors and healthcare providers, slowing market expansion. Overcoming these challenges requires standardized protocols and extensive validation, which can be time-consuming and costly.
• Regulatory and Ethical Hurdles: The regulatory landscape for microbiome-based products remains underdeveloped and complex. Approvals for microbiome therapeutics and diagnostics involve rigorous clinical trials and safety assessments, which can delay product launches. Ethical concerns related to fecal microbiota transplants and microbiome manipulation also pose barriers, especially regarding donor screening, consent, and long-term safety. Variability in regulatory frameworks across regions complicates international commercialization. Addressing these hurdles necessitates clear guidelines, robust safety data, and ethical standards, which require significant time and resources.
• Market Fragmentation and Lack of Standardization: The human microbiome market is highly fragmented, with numerous small players and diverse product offerings. This fragmentation hampers standardization of microbiome analysis techniques, data interpretation, and product quality. Lack of universally accepted protocols and benchmarks limits comparability and reproducibility of research findings. Consequently, this hampers regulatory approval and clinical acceptance. Market fragmentation also leads to intense competition, price pressures, and challenges in establishing brand trust. Overcoming these issues requires industry-wide standards, collaborative frameworks, and quality assurance measures to ensure consistent and reliable microbiome products.

The human microbiome market is driven by technological innovations, increasing disease prevalence, substantial investments, growing therapy adoption, and expanding research collaborations. However, scientific uncertainties, regulatory complexities, and market fragmentation pose significant challenges. These drivers and challenges collectively shape the market's trajectory, influencing innovation, investment, and commercialization strategies. While opportunities for growth are substantial, addressing scientific and regulatory hurdles is crucial for sustainable development. Overall, the market's evolution will depend on how effectively stakeholders navigate these dynamics to unlock the microbiome's full therapeutic and diagnostic potential.

List of Human Microbiome Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies human microbiome market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human microbiome market companies profiled in this report include-

• Enterome
• Seres Therapeutics
• 4D Pharma
• DuPont
• Vedanta Biosciences
• Osel
• Merck & Co.

Human Microbiome Market by Segment

The study includes a forecast for the global human microbiome market by product, disease type, technology, application, and region.

Human Microbiome Market by Product [Value ($B) from 2019 to 2035]:

• Prebiotics
• Probiotics
• Food
• Medical Food
• Drugs

Human Microbiome Market by Disease Type [Value ($B) from 2019 to 2035]:

• Infectious
• Metabolic/ Endocrine
• Cancer
• Blood
• Neurological

Human Microbiome Market by Technology [Value ($B) from 2019 to 2035]:

• Proteomics
• Metabolomics
• Genomics

Human Microbiome Market by Application [Value ($B) from 2019 to 2035]:

• Therapeutics
• Diagnostics

Human Microbiome Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Human Microbiome Market

The human microbiome market has experienced rapid growth driven by advances in biotechnology, increasing awareness of microbiome health, and expanding applications in personalized medicine, diagnostics, and therapeutics. As research uncovers the microbiome's role in various health conditions, countries are investing heavily in innovation, regulatory frameworks, and collaborations to capitalize on this emerging field. The market's evolution reflects a global shift towards microbiome-based solutions for disease prevention and treatment, with key players focusing on product development, clinical trials, and commercialization strategies. This dynamic landscape is shaping the future of healthcare, emphasizing the importance of microbiome research across different regions.

• United States: The US leads in microbiome research and commercialization, with significant investments from biotech firms and government agencies like NIH. Recent developments include the approval of microbiome-based therapeutics and expansion of clinical trials focusing on gastrointestinal and metabolic disorders. Major companies are forming strategic partnerships to develop personalized microbiome treatments, and regulatory agencies are working to establish clear guidelines for product approval. The US also sees increased consumer interest in microbiome testing kits, fueling market growth and innovation.
• China: China has rapidly advanced in microbiome research, supported by government initiatives and substantial funding. Recent developments include the launch of large-scale microbiome projects and the establishment of research centers dedicated to microbiome science. Chinese companies are developing microbiome-based products for digestive health and immune support, with a focus on integrating traditional medicine with modern biotechnology. The market is also witnessing increased collaborations with international firms, aiming to accelerate product development and regulatory approval processes.
• Germany: Germany remains a key player in microbiome research within Europe, with a focus on clinical applications and diagnostics. Recent advancements include the development of microbiome analysis tools and probiotic formulations for gastrointestinal health. German research institutions are actively involved in European Union-funded projects to explore microbiome's role in chronic diseases. The country emphasizes regulatory compliance and quality standards, fostering innovation in microbiome therapeutics and personalized nutrition solutions.
• India: India is emerging as a significant market for microbiome research, driven by rising awareness of gut health and increasing investment in biotech startups. Recent developments include the launch of microbiome-based diagnostic services and probiotic products tailored to local populations. The government is promoting microbiome research through funding and policy support, aiming to integrate traditional Ayurvedic practices with modern microbiome science. The market is also witnessing collaborations between academia and industry to develop affordable microbiome solutions for widespread health issues.
• Japan: Japan has a strong focus on microbiome research, particularly in aging and metabolic health. Recent advancements include the development of microbiome-targeted therapies and functional foods. Japanese companies are exploring microbiome modulation to improve health outcomes in elderly populations, with several products in clinical trials. The government supports microbiome research through funding and regulatory initiatives, fostering innovation in personalized nutrition and therapeutics. Japan's emphasis on integrating traditional dietary practices with modern science positions it as a leader in microbiome-based health solutions.

Features of the Global Human Microbiome Market

• Market Size Estimates: human microbiome market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
• Segmentation Analysis: human microbiome market size by various segments, such as by product, disease type, technology, application, and region in terms of value ($B).
• Regional Analysis: human microbiome market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different product, disease type, technology, application, and regions for the human microbiome market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human microbiome market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the human microbiome market by product (prebiotics, probiotics, food, medical food, and drugs), disease type (infectious, metabolic/ endocrine, cancer, blood, and neurological), technology (proteomics, metabolomics, and genomics), application (therapeutics and diagnostics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Human Microbiome Market by Product

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product
• 4.3 Prebiotics : Trends and Forecast (2019 to 2035)
• 4.4 Probiotics : Trends and Forecast (2019 to 2035)
• 4.5 Food : Trends and Forecast (2019 to 2035)
• 4.6 Medical Food : Trends and Forecast (2019 to 2035)
• 4.7 Drugs : Trends and Forecast (2019 to 2035)

5. Global Human Microbiome Market by Disease Type

• 5.1 Overview
• 5.2 Attractiveness Analysis by Disease Type
• 5.3 Infectious : Trends and Forecast (2019 to 2035)
• 5.4 Metabolic/ Endocrine : Trends and Forecast (2019 to 2035)
• 5.5 Cancer : Trends and Forecast (2019 to 2035)
• 5.6 Blood : Trends and Forecast (2019 to 2035)
• 5.7 Neurological : Trends and Forecast (2019 to 2035)

6. Global Human Microbiome Market by Technology

• 6.1 Overview
• 6.2 Attractiveness Analysis by Technology
• 6.3 Proteomics : Trends and Forecast (2019 to 2035)
• 6.4 Metabolomics : Trends and Forecast (2019 to 2035)
• 6.5 Genomics : Trends and Forecast (2019 to 2035)

7. Global Human Microbiome Market by Application

• 7.1 Overview
• 7.2 Attractiveness Analysis by Application
• 7.3 Therapeutics : Trends and Forecast (2019 to 2035)
• 7.4 Diagnostics : Trends and Forecast (2019 to 2035)

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Human Microbiome Market by Region

9. North American Human Microbiome Market

• 9.1 Overview
• 9.2 North American Human Microbiome Market by Product
• 9.3 North American Human Microbiome Market by Application
• 9.4 The United States Human Microbiome Market
• 9.5 Canadian Human Microbiome Market
• 9.6 Mexican Human Microbiome Market

10. European Human Microbiome Market

• 10.1 Overview
• 10.2 European Human Microbiome Market by Product
• 10.3 European Human Microbiome Market by Application
• 10.4 German Human Microbiome Market
• 10.5 French Human Microbiome Market
• 10.6 Italian Human Microbiome Market
• 10.7 Spanish Human Microbiome Market
• 10.8 The United Kingdom Human Microbiome Market

11. APAC Human Microbiome Market

• 11.1 Overview
• 11.2 APAC Human Microbiome Market by Product
• 11.3 APAC Human Microbiome Market by Application
• 11.4 Chinese Human Microbiome Market
• 11.5 Indian Human Microbiome Market
• 11.6 Japanese Human Microbiome Market
• 11.7 South Korean Human Microbiome Market
• 11.8 Indonesian Human Microbiome Market

12. ROW Human Microbiome Market

• 12.1 Overview
• 12.2 ROW Human Microbiome Market by Product
• 12.3 ROW Human Microbiome Market by Application
• 12.4 Middle Eastern Human Microbiome Market
• 12.5 South American Human Microbiome Market
• 12.6 African Human Microbiome Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Product
  • 14.2.2 Growth Opportunity by Disease Type
  • 14.2.3 Growth Opportunity by Technology
  • 14.2.4 Growth Opportunity by Application
  • 14.2.5 Growth Opportunity by Region
• 14.3 Emerging Trends in the Global Human Microbiome Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 Enterome
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Seres Therapeutics
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 4D Pharma
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 DuPont
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Vedanta Biosciences
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Osel
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 Merck & Co.
  • Company Overview
  • Human Microbiome Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us